Getting the most out of AI foundation models: tips for pharmaceutical companies

An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics.

We’ve all heard of and used ChatGPT. But what if we could apply this to pharmaceutical R&D? To effectively use AI for business and patient outcomes, a fundamental technological, cultural and organizational shift is required.

Most previous efforts to use AI for drug discovery have fallen flat, but in the past two years there have been radical advancements in AI that could transform the pharmaceutical industry. AI foundation models have demonstrated potential for accelerating drug discovery, optimizing clinical trials and even predicting possible adverse effects.